Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Aug 5, 2024 | Non-Hodgkin Lymphoma
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques May 10, 2024 | HIV
Safety and virologic impact of haploidentical NK cells plus IL-2 or N-803 in HIV infection May 10, 2024 | HIV
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques May 10, 2024 | HIV
Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach May 10, 2024 | Uncategorized
